Table 5.

Prevalence (%) of Variants Based on the Carboxy Terminus of EBNA-1 by Clinical Condition and Geographic Region

Clinical Condition	EBNA-1 Genotype	China	Africa	South America	North America	Europe
NPC	P-ala	0.0%				18.2%
	P-thr	4.0%				72.7%
	V-val	95.2%				0.0%
	V-leu	0.0%				0.0%
	V-pro	0.0%				0.0%
	Multiple/Other	0.8%a				9.1%d
	Total Cases	125	0	0	0	11
BL	P-ala		2.5%	0.0%		60.0%
	P-thr		41.8%	8.3%		40.0%
	V-val		0.0%	0.0%		0.0%
	V-leu		54.4%	75.0%		0.0%
	V-pro		1.3%	0.0%		0.0%
	Multiple/Other		0.0%	16.7%c		0.0%
	Total Cases	0	79	12	0	2
HL	P-ala	0.0%		0.0%	16.7%	13.6%
	P-thr	0.0%		25.0%	50.0%	81.8%
	V-val	100%		0.0%	0.0%	0.0%
	V-leu	0.0%		75.0%	33.3%	4.5%
	V-pro	0.0%		0.0%	0.0%	0.0%
	Multiple/Other	0.0%		0.0%	0.0%	0.0%
	Total Cases	2	0	20	12	22
AIDS lymphoma	P-ala			20.0%	15.8%	36.7%
	P-thr			40.0%	31.6%	38.8%
	V-val			0.0%	0.0%	2.0%
	V-leu			20.0%	26.3%	8.2%
	V-pro			0.0%	0.0%	0.0%
	Multiple/Other			20.0%3	26.3%d	14.3%f
	Total Cases	0	0	5	19	49
Healthy/nonmalignant	P-ala	16.2%	5.3%	16.7%	46.4%	40.0%
	P-thr	2.7%	36.8%	33.3%	17.9%	55.0%
	V-val	48.6%	0.0%	0.0%	0.0%	0.0%
	V-leu	0.0%	47.4%	50%	0.0%	2.5%
	V-pro	0.0%	0.0%	0.0%	0.0%	0.0%
	Multiple/Other	32.4%a	10.5%b	0.0%	35.7%e	2.5%d
	Total Cases	37	38	6	28	8

(Bhatia et al., 1996; Chang et al., 1999; Do et al., 2008; Fassone et al., 2002; Gutierrez et al., 2000; Gutierrez et al., 1997; MacKenzie et al., 1999; Sandvej et al., 2000; Wang et al., 2003; Wang et al., 2002; Zhang et al., 2004)

^aV-val + P-ala;

^bP-ala/thr + V-pro;

^cV-ala;

^dNot specified;

^eP-ala + P-thr/V-val

^fP-ala + P-thr